Stigma and psychosocial problems in patients with epilepsy

Yeni, Kubra

doi:10.37349/en.2023.00026

Cited by 4 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By accurately identifying and categorizing seizure types, healthcare providers can choose treatment to address the specific needs of individuals with epilepsy. Despite advancements in treatment, epilepsy can still pose significant difficulties to those affected, impacting daily activities, social interactions, and mental well-being [ 32 ]. Seizures that persist despite treatment with antiepileptic drugs present a significant challenge in epilepsy management.…”

Section: Introductionmentioning

confidence: 99%

The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders

Stasiłowicz-Krzemień,

Nogalska,

Maszewska

et al. 2024

IJMS

View full text Add to dashboard Cite

Neurological disorders present a wide range of symptoms and challenges in diagnosis and treatment. Cannabis sativa, with its diverse chemical composition, offers potential therapeutic benefits due to its anticonvulsive, analgesic, anti-inflammatory, and neuroprotective properties. Beyond cannabinoids, cannabis contains terpenes and polyphenols, which synergistically enhance its pharmacological effects. Various administration routes, including vaporization, oral ingestion, sublingual, and rectal, provide flexibility in treatment delivery. This review shows the therapeutic efficacy of cannabis in managing neurological disorders such as epilepsy, neurodegenerative diseases, neurodevelopmental disorders, psychiatric disorders, and painful pathologies. Drawing from surveys, patient studies, and clinical trials, it highlights the potential of cannabis in alleviating symptoms, slowing disease progression, and improving overall quality of life for patients. Understanding the diverse therapeutic mechanisms of cannabis can open up possibilities for using this plant for individual patient needs.

show abstract

Section: Introductionmentioning

confidence: 99%

The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders

Stasiłowicz-Krzemień,

Nogalska,

Maszewska

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

A multicultural comparative study of self‐stigma in epilepsy: Differences across four cultures

Iwayama,

Mizuno,

Yildiz

et al. 2024

Epilepsia Open

View full text Add to dashboard Cite

ObjectiveEpilepsy is a neurological disorder characterized by recurrent seizures, exhibiting variance in prevalence and treatment availability across diverse geopolitical contexts and cultural milieus. The stigma associated with epilepsy is a significant global issue affecting the quality of life (QOL) of people with epilepsy (PWE). This study aims to examine the relationship between self‐stigma and depressive symptoms in PWE, with a particular emphasis on understanding the manifestations of these across different cultural contexts. We aim to enhance the provision of customized care to diverse cultural settings, fostering the adoption of healthier lifestyles for PWE.MethodsWe recruited PWE who received treatment at specialized medical facilities for epilepsy in Japan, Malaysia (Chinese, Malay), and Turkey from February to October 2023. The Epilepsy Self‐Stigma Scales (ESSS), Neurological Disorders Depression Inventory for Epilepsy (NDDI‐E), and Generalized Anxiety Disorder 7 (GAD‐7) in local languages were used to assess self‐stigma, depressive symptoms, and anxiety.ResultsThe ESSS total scores were significantly higher among the Turkish and Japanese cohorts (F [3, 406] = 6.57, p < 0.001, η2 = 0.05). In addition, the self‐stigma observed moderate positive correlations for depressive symptoms (rs = 0.41–0.50, Ps < 0.001) and anxiety (rs = 0.42–0.44, Ps < 0.001). The ANCOVA findings suggested that the notable variations in self‐stigma, as found in the one‐way ANOVA conducted across four cultures, were reduced when taking into consideration depressed symptoms. Our finding highlights the potential influence of mental health factors over cultural factors concerning self‐stigma.SignificanceThe manifestation of self‐stigmatization within epilepsy exhibits distinctions across diverse cultural cohorts, regardless of the demographic and clinical variation, yet demonstrates a significant correlation with psychological factors. In subsequent research endeavors, we should comprehensively investigate these subtle differences, their potential impact on patient care, and the development of supportive approaches.Plain Language SummaryThis cross‐cultural study reveals significant variations in self‐stigma among people with epilepsy across different cultural contexts, with Turkish and Japanese cohorts showing higher levels. Self‐stigma demonstrated moderate positive correlations with depressive symptoms and anxiety across all cultures. Notably, differences in self‐stigma were reduced when accounting for depressive symptoms, suggesting that mental health factors may have a stronger influence than cultural factors. These findings underscore the importance of considering both cultural and psychological aspects in developing targeted interventions to address self‐stigma in epilepsy care.

show abstract

Understanding the Burden of Lennox−Gastaut Syndrome: Implications for Patients, Caregivers, and Society in High and Low Resource Settings: A Narrative Review

Mourid,

Oduoye

2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundLennox−Gastaut syndrome (LGS) poses significant challenges in diagnosis, management, and treatment due to its rare nature, diverse presentation, and drug‐resistant seizures. While classical features aid diagnosis, challenges persist, impacting patient care and outcomes. Understanding the syndrome's burden is essential for improving healthcare policies and interventions.AimThis literature review aimed to comprehensively analyze clinical symptom burden, comorbidities, care requirements, quality of life (QoL), economic burden, caregiver burden, and treatment burden to pinpoint knowledge gaps for future research and intervention development, ultimately aiming to enhance the well‐being of patients and caregivers.MethodsA comprehensive literature review was conducted using electronic databases and manual searches to analyze clinical symptom burden, comorbidities, care requirements, QoL, economic burden, caregiver burden, and treatment burden associated with LGS.ResultsLGS significantly impacts the QoL for patients, with seizures, cognitive impairment, and social challenges affecting various aspects of daily living. Caregivers, particularly mothers, face significant stress and exhaustion, impacting their own health and well‐being. Healthcare resource utilization is substantial, with elevated costs for LGS patients compared to controls. Cognitive impairment is prevalent and worsens over time, influencing educational and social outcomes. Prognosis varies based on factors like age of onset, underlying cause, and genetic factors, with limited treatment options available.ConclusionManaging LGS requires tailored approaches addressing seizures, comorbidities, and caregiver needs. While advancements in treatments and surgical techniques offer hope, challenges persist in achieving optimal outcomes and reducing the societal burden. The management of LGS involves a combination of pharmacological and nonpharmacological therapies, tailored to the individual patient's needs and response to treatment. Regular follow‐up with a neurologist specialized in epilepsy is crucial for ongoing management, including annual reassessment of the diagnosis and treatment plan. The primary focus should always be on optimizing the patient's QoL, including learning and behavioral management, as complete seizure remission is rare.

show abstract

Stigma and psychosocial problems in patients with epilepsy

Cited by 4 publications

References 81 publications

The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders

The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders

A multicultural comparative study of self‐stigma in epilepsy: Differences across four cultures

Understanding the Burden of Lennox−Gastaut Syndrome: Implications for Patients, Caregivers, and Society in High and Low Resource Settings: A Narrative Review

Contact Info

Product

Resources

About